

**AMENDMENTS TO THE SPECIFICATION:**

Page 64, before line 1, please insert as follows:

**Brief Description of the Drawings**

Figure 1a depicts *in vivo* activity of compound Ib-7 and its corresponding phosphate pre-prodrug Ib-7P, relative to the known hypoxic cytotoxin tirapazamine;

Figure 1b depicts an excision assay method: 300-500mg Rif-1 xenograft→ 15Gy→ Single prodrug dose @ MTD→ 18hr→ excision→ disaggregate→ plate  $10^2$ - $10^5$  cells → 12 days→ colonies counted;

Figure 2a depicts *in vivo* activity of compound Ib-7 and its corresponding phosphate pre-prodrug, Ib-7P, against human colon carcinoma xenografts grown by inoculating mixtures of 90% NTR – ve and 10% NTR+ve Wi Dr cells;

Figure 2b are plots of % animals survival versus time(days), in which open circles denote wild-type WiDR human colon carcinoma xenografts, and filled circles denote tumours containing WiDr cells transfected with the *E. coli* NTR gene;

Figure 3a is a plot of plasma concentration versus time (min) for compound Ib-2mP in female CD-1 mice;

Figure 3b is a plot of plasma concentration versus time (min) for compound Ib-7P in female CD-1 mice;

Figure 3c is a plot of plasma concentration versus time (min) for compound Ib-12P in female CD-1 mice;

Figure 3d is a plot of plasma concentration versus time (min) for compound Ic-12P in female CD-1 mice.

Page 66, please delete in its entirety.

Page 69, please delete in its entirety.

Page 70, please delete the four illustrations beginning at lines 11-12 (prior to the last paragraph).